Mark E. Morrison
Impact in
- Oncology top 5%
- Lung Cancer Research Studies
- Peptidase Inhibition and Analysis
- Epidemiology top 10%
- Neuroendocrine Tumor Research Advances
Papers in
-
- Retinoids in leukemia and cellular processes 1
- Cancer therapeutics and mechanisms 1
- Oncology 3
- Peptidase Inhibition and Analysis 2
- Co-authors
- Hariharan Subramanian (2 shared papers)Paul A. Bunn (1 shared paper)Troy H. Guthrie (1 shared paper)Peter Ellis (1 shared paper)Rafat Ansari (1 shared paper)Benjamin Wang (1 shared paper)Lawrence H. Einhorn (1 shared paper)Corey J. Langer (1 shared paper)
- Journals
- Journal of Clinical Oncology (2 papers)The Journal of Experimental Medicine (1 paper)Biochemistry (1 paper)Proceedings of the National Academy of Sciences (1 paper)Genomics (1 paper)
- Partner nations
- United States
In The Last Decade
Mark E. Morrison
6 papers receiving 724 citations
Mark E. Morrison's Hit Papers
Peers
Comparison fields: 5 of 59
- Oncology 647
- Epidemiology 429
- Molecular Biology 338
- Physiology 21
- Pulmonary and Respiratory Medicine 142
Countries citing papers authored by Mark E. Morrison
This map shows the geographic impact of Mark E. Morrison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E. Morrison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E. Morrison more than expected).
Fields of papers citing papers by Mark E. Morrison
This network shows the impact of papers produced by Mark E. Morrison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E. Morrison. The network helps show where Mark E. Morrison may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark E. Morrison, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer Hit paper breakdown → | 2006 | 500 |
| 2 | 1993 | 143 | |
| 3 | 2006 | 53 | |
| 4 | 1985 | 33 | |
| 5 | 1983 | 14 | |
| 6 | 1994 | 7 |
About Mark E. Morrison
Mark E. Morrison is a scholar working on Molecular Biology, Oncology, Organic Chemistry, Epidemiology and Cell Biology, having authored 6 papers that have together received 750 indexed citations. Recurring topics across this work include melanin and skin pigmentation (2 papers), Neuroendocrine Tumor Research Advances (2 papers), Peptidase Inhibition and Analysis (2 papers), Inflammatory mediators and NSAID effects (1 paper), Computational Drug Discovery Methods (1 paper), Retinoids in leukemia and cellular processes (1 paper), Cancer therapeutics and mechanisms (1 paper) and Diabetes Treatment and Management (1 paper). The work is most often cited by research in Oncology (647 citations), Epidemiology (429 citations), Molecular Biology (338 citations), Physiology (21 citations) and Pulmonary and Respiratory Medicine (142 citations). Mark E. Morrison has collaborated with scholars based in United States. Frequent co-authors include Hariharan Subramanian, Paul A. Bunn, Troy H. Guthrie, Peter Ellis, Rafat Ansari, Benjamin Wang, Lawrence H. Einhorn, Corey J. Langer, Alan Sandler and Nasser H. Hanna. Their work appears in journals such as Journal of Clinical Oncology, The Journal of Experimental Medicine, Biochemistry, Proceedings of the National Academy of Sciences and Genomics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.